Dong Wan Kim

TL;DR: TNBC with high Ki-67 was associated with a more aggressive clinical feature despite a higher pCR rate, and high proliferation index Ki- 67 can be used for further classification of TNBC into two subtypes with different responses and prognosis.

TL;DR: The comprehensively analyzed the immunogenomic properties in The Cancer Genome Atlas according to the classification of tumor into four groups based on PD-L1 status and tumor-infiltrating lymphocyte recruitment to predict responders to immune checkpoint inhibitors found TMIT I to be associated with a high mutational burden, PD- L1 amplification, and oncogenic viral infection.

TL;DR: Brigatinib represents a once-daily ALK inhibitor with superior efficacy, tolerability, and QoL over crizotinib, making it a promising first-line treatment of ALK-positive NSCLC.

TL;DR: Continuing ALK inhibition with crizotinib after PD may provide survival benefit to patients with advanced ALK-positive NSCLC and patients who continued CBPD were more likely to have good ECOG PS at the time of PD.

TL;DR: CC with DP after CCRT with weekly DP in LA-NSCLC failed to further prolong PFS, and C CRT alone should remain the standard of care.